0000000000085500

AUTHOR

Marcello Maida

showing 53 related works from this author

Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data

2022

Background: The COVID-19 outbreak has led IBD clinics to adopt a remote monitoring approach in order to guarantee an adequate follow-up of patients with inflammatory bowel disease (IBD) and ensure the rules of social distancing. Aim: The aim of the study was to perform a survey on IBD patients who underwent remote monitoring in our tertiary referral center, to assess adherence, patients’ perceptions and satisfaction, and finally their opinions for future monitoring. Furthermore, we evaluated changes in disease activity and Quality of Life (QoL) using validated questionnaires. Methods: Consecutive patients with IBD scheduled for follow-up visits were switched to remote monitoring throu…

inflammatory bowel disease; COVID-19; telemedicine; ulcerative colitis; Crohn’s DiseaseHepatologyinflammatory bowel diseaseGastroenterologyCrohn's Disease.COVID-19telemedicineulcerative coliti
researchProduct

COVID-19 and the Pancreas: A Narrative Review.

2022

The outbreak of COVID-19, initially developed in China in early December 2019, has rapidly spread to other countries and represents a public health emergency of international concern. COVID-19 has caused great concern about respiratory symptoms, but it is worth noting that it can also affect the gastrointestinal tract. However, the data on pancreatic involvement during SARS-CoV-2 infection are limited. The prevalence and severity of pancreatic damage and acute pancreatitis, as well as its pathophysiology, are still under debate. Moreover, the possible implication of pancreatic damage as an apparent adverse effect of COVID-19 therapies or vaccines are issues that need to be addressed. Finall…

coronavirupancreaSettore MED/12 - GastroenterologiaSARS-CoV-2Space and Planetary ScienceCOVID-19Paleontologypancreatitis.General Biochemistry Genetics and Molecular BiologyEcology Evolution Behavior and SystematicsSettore MED/13 - EndocrinologiaLife (Basel, Switzerland)
researchProduct

Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.

2014

Background & Aims: In Chronic Hepatitis C (CHC), the influence of steatosis on liver stiffness measurement (LSM) is still debated. We assessed the impact of steatosis and its ultrasonographical sign – bright liver echo pattern (BLEP) – on LSM values and on transient elastography (TE) accuracy for the diagnosis of liver fibrosis, in a cohort of consecutive patients with Genotype 1 (G1) CHC. Methods: Patients (n = 618) were assessed by clinical, ultrasonographic and histological (Scheuer score) features. TE was performed using the M probe. Results: Male gender (p = 0.04), steatosis as continuous variable (p <0.001), severity of necroinflammation (p = 0.02) and stage of fibrosis (p <0.001) wer…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisGenotypeBiopsyComorbidityHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologySensitivity and SpecificitySeverity of Illness IndexCohort StudiesFibrosisInternal medicineUltrasoundmedicineHumansNon-invasiveEvaluationAgedRetrospective StudiesUltrasonographySettore MED/12 - GastroenterologiaCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseElasticityFatty LiverLiverLiver biopsyCohortFibroscan®Cirrhosis; Evaluation; Fibroscan®; Non-invasive; UltrasoundFemaleSteatosisbusinessTransient elastographyJournal of hepatology
researchProduct

Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.

2017

Abstract Background Few studies investigated the role of mycophenolate mofetil in inflammatory bowel disease, and none of them had specifically focused on patients with previous multiple intolerances and/or nonresponses to conventional immunosuppressants and biologics. Aims To evaluate clinical benefit and tolerability profile of mycophenolate mofetil in patients with inflammatory bowel disease and limited treatment options. Methods All consecutive patients with previous multiple intolerances and/or nonresponses to immunosuppressants and biologics who started an off-label treatment with mycophenolate mofetil from January 2014 to February 2016 were entered in a prospectively maintained datab…

AdultMalemedicine.medical_specialtyDrug ResistanceKaplan-Meier EstimateMycophenolateInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineIntolerancesInternal medicineMedicineHumansIn patientEnzyme InhibitorsAgedCrohn's diseaseBiological ProductsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisDiscontinuationTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyFemalebusinessImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

P215 Blood-based prognostic biomarkers in Crohn’s patients treated with biologics: a new promising tool to predict endoscopic outcomes

2021

Abstract Background There is a growing need for biomarkers of inflammation to monitor and predict therapeutic outcome in Crohn’s disease (CD) patients. We aimed to evaluate whether the level of circulating blood cells, expressed as ratios (NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ELR, eosinophil-to-lymphocyte ratio and ENLR, eosinophil*neutrophil-to-lymphocyte ratio), could be used as early prognostic biomarker of endoscopic response (ER) in patients starting biological therapy with infliximab, adalimumab, vedolizumab and ustekinumab. Association with steroid-free clinical remission at week 54 and endoscopic disease activity at baseline, as well as other varia…

medicine.medical_specialtyCrohn's diseasePredictive markermedicine.diagnostic_testbusiness.industryGastroenterologyInflammationGeneral Medicinemedicine.diseaseGastroenterologyInfliximabVedolizumabEndoscopyInternal medicineUstekinumabmedicineAdalimumabmedicine.symptombusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Assessment of treatment response in hepatocellular carcinoma: a review of the literature

2013

Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application an…

OncologyCancer ResearchTreatment responsemedicine.medical_specialtyCarcinoma HepatocellularLiver Function TestsInternal medicineClinical endpointHumansMedicineResponse criteriaNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industrySurrogate endpointIncidence (epidemiology)Liver NeoplasmsGeneral MedicinePrognosismedicine.diseaseSurvival Analysisdigestive system diseasesRadiographyClinical PracticeTreatment OutcomeOncologyRadiological weaponHepatocellular carcinomabusinessFuture Oncology
researchProduct

The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection

2014

Pathologymedicine.medical_specialtyHepatologyHcv genotype 1business.industryGastroenterologyMedicineIn patientSteatosisbusinessmedicine.diseaseDigestive and Liver Disease
researchProduct

Screening of colorectal cancer: present and future

2017

Colorectal cancer (CRC) is the third most common cancer in males and second in females, and the fourth most common cause of cancer death worldwide. Currently, about 60-70% of diagnosed cases in symptomatic patients are detected at an advanced stage of disease. Earlier stage detection through the use of screening strategies would allow for better outcomes in terms of reducing the disease burden. Areas covered: The aim of this paper is to review the current published evidence from literature which assesses the performance and effectiveness of different screening tests for the early detection of CRC. Expert commentary: Adequate screening strategies can reduce CRC incidence and mortality. In th…

medicine.medical_specialtyTime FactorsColorectal cancerSettore MED/12 - GASTROENTEROLOGIAEarly detectionDisease03 medical and health sciences0302 clinical medicinemedicineHumansMass ScreeningPharmacology (medical)Stage (cooking)Intensive care medicineEarly Detection of CancerNeoplasm StagingGynecologygFOBTCrc screeningbusiness.industryIncidence (epidemiology)screeningAdvanced stageCancerColonoscopycolonscopymedicine.diseaseFITColorectal cancercolonscopy; Colorectal cancer; FIT; gFOBT; screening; surveillance; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Mass Screening; Neoplasm Staging; Practice Guidelines as Topic; Time Factors; Oncology; Pharmacology (medical)Oncology030220 oncology & carcinogenesisPractice Guidelines as Topicsurveillance030211 gastroenterology & hepatologybusinessColorectal Neoplasms
researchProduct

Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Donʼt Forget the Role of Cyclosporin

2012

medicine.medical_specialtybusiness.industryGastroenterologymedicineImmunology and Allergymedicine.diseasebusinessUlcerative colitisDermatologyPyoderma gangrenosumInfliximabmedicine.drugInflammatory Bowel Diseases
researchProduct

Genetic background in nonalcoholic fatty liver disease: A comprehensive review

2015

In the Western world, nonalcoholic fatty liver disease (NAFLD) is considered as one of the most significant liver diseases of the twenty-first century. Its development is certainly driven by environmental factors, but it is also regulated by genetic background. The role of heritability has been widely demonstrated by several epidemiological, familial, and twin studies and case series, and likely reflects the wide inter-individual and inter-ethnic genetic variability in systemic metabolism and wound healing response processes. Consistent with this idea, genome-wide association studies have clearly identified Patatin-like phosholipase domain-containing 3 gene variant I148M as a major player i…

Genetic MarkersCandidate geneGenome-wide association studieHeredityPatatin-like phospholipase domain-containing 3Genome-wide association studyDiseaseReviewBiologymedicine.disease_causeGeneticNon-alcoholic Fatty Liver DiseaseRisk FactorsHeredityNonalcoholic fatty liver diseasemedicineHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic variabilityGenetic associationGeneticsFatty liverGastroenterologyGenetic VariationGeneral Medicinemedicine.diseaseCandidate gene studiePedigreePhenotypeNonalcoholic steatohepatitiTransmembrane 6 superfamily member 2Candidate gene studies; Genetics; Genome-wide association studies; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Patatin-like phospholipase domain-containing 3; Transmembrane 6 superfamily member 2Genome-Wide Association Study
researchProduct

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.

2015

Hepatocellular carcinoma is a challenging malignancy of global importance. It is the sixth most common solid malignancy and the third leading cause of cancer-related death, worldwide. Curative treatments at early stages include liver transplantation, resection and percutaneous ablation, while transarterial chemoembolization can improve survival in patients with intermediate tumor stage. Patients with mild, related symptoms and/or macrovascular invasion or extrahepatic spread are classified under the advanced stage. The standard of care in this group is sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor, whose effectiveness has been proven by 2 recent rando…

SHARPOncologyHepatocellular carcinomamedicine.medical_treatmentOLTLiver transplantationGastroenterologyLiver cirrhosilaw.inventionAntineoplastic AgentRandomized controlled triallawPractice Patterns Physicians'Randomized Controlled Trials as TopicNexavarMedicine (all)Liver NeoplasmsGastroenterologyGeneral MedicineSorafenibLocoregional therapiePercutaneous ethanol injectionLiver NeoplasmRaf kinaseHepatocellular carcinomaLiver cancerLiver cancerHumanmedicine.drugSorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsMalignancyTransarterial chemoembolizationInternal medicinemedicineCarcinomaChemotherapyHumansChemoembolization Therapeuticbusiness.industryPhenylurea CompoundsRadiofrequency ablationResectionmedicine.diseaseBCLCPercutaneous ethanol injectionbusinessDigestive diseases (Basel, Switzerland)
researchProduct

Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist

2013

Primary biliary cirrhosis is a slowly progressive cholestatic autoimmune liver disease that mainly affects middle- aged women with an estimated prevalence ranging from 6.7 to 402 cases per million. Hereditary hemorrhagic telangiectasia, or Rendu-Osler-Weber disease, is an autosomal dominant disorder characterized by angiodysplastic lesions (telangiectases and arteriovenous malformations) that can affect many organs, including liver, with a prevalence of 1-2 cases per 10000. We describe the coexistence, for the first time to our knowledge, of these two rare diseases in a 50-year old Caucasian woman. In this setting, the relevance of an accurate medical history, the role of liver histology an…

Pathologymedicine.medical_specialtySettore MED/12 - GastroenterologiaPrimary biliary cirrhosiHepatologybusiness.industryFocal nodular hyperplasiaCase ReportDiseaseTelangiectasesImmunostainingSettore MED/08 - Anatomia Patologicamedicine.diseaseUrsodeoxycholic acidPrimary biliary cirrhosisHereditary hemorragic telangiectasiaUrsodeoxycholic acidFocal nodular hyperplasiamedicineMedical historymedicine.symptomAutoimmune liver diseasebusinessTelangiectasiamedicine.drug
researchProduct

Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma

2015

Background & aims To develop an individual prognostic calculator for patients with unresectable hepatocellular carcinoma (HCC) undergoing trans-arterial chemo-embolization (TACE). Methods Data from two prospective databases, regarding 361 patients who received TACE as first-line therapy (2000-2012), were reviewed in order to refine available prognostic tools and to develop a continuous individual web-based prognostic calculator. Patients with neoplastic portal vein invasion were excluded from the analysis. The model was built following a bootstrap resampling procedure aimed at identifying prognostic predictors and by carrying out a 10-fold cross-validation for accuracy assessment by means o…

MaleOncologymedicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaPrognosimedicine.medical_treatmentPortal veinEmbolization03 medical and health sciences0302 clinical medicineText miningSerum total bilirubinInternal medicineBiomarkers TumorHumansMedicineProspective StudiesEmbolizationChemoembolization TherapeuticAgedHepatologyPortal Veinbusiness.industryLiver NeoplasmsBilirubinMiddle AgedPrognosismedicine.diseaseSurvival AnalysisSurgeryClinical PracticeItaly030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisCohortTrans-arterial chemo-embolizationPrognostic modelFemale030211 gastroenterology & hepatologybusinessLiver International
researchProduct

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct

P178 Remote monitoring as an effective management strategy in inflammatory bowel disease: the lesson from COVID-19 pandemic

2021

Abstract Background During the COVID-19 outbreaks many IBD clinics in Italy adopted a remote monitoring approach both to ensure an adequate follow-up of patients with inflammatory bowel disease (IBD) and respect the rules of social distancing, while access to hospital was restricted. Aim of the study was to perform a survey on IBD patients submitted to remote monitoring in our tertiary referral center in order to assess adherence and patients’ perceptions and satisfaction as well as their opinions for future monitoring. Changes in disease activity and Quality of Life were also evaluated. Methods Consecutive patients with IBD scheduled for follow-up visits were switched to remote monitoring …

Crohn's disease2019-20 coronavirus outbreakmedicine.medical_specialtyTelemedicineCoronavirus disease 2019 (COVID-19)business.industryGastroenterologyEffective managementGeneral Medicinemedicine.diseaseClinical: Diagnosis and OutcomeInflammatory bowel diseasePoster presentationsQuality of life (healthcare)PandemicMedicinebusinessIntensive care medicineAcademicSubjects/MED00260Journal of Crohn's and Colitis
researchProduct

Staging systems of hepatocellular carcinoma: A review of literature

2013

Hepatocellular carcinoma (HCC) is a major health problem with a high incidence and mortality all over the world. Natural history of HCC is severe and extremely variable, and prognostic factors influencing outcomes are incompletely defined. Over time, many staging and scoring systems have been proposed for the classification and prognosis of patients with HCC. Currently, the non-ideal predictive performance of existing prognostic systems is secondary to their inherent limitations, as well as to a non-universal reproducibility and transportability of the results in different populations. New serological and histological markers are still under evaluation with promising results, but they requi…

Oncologymedicine.medical_specialtyAsiaCarcinoma HepatocellularTime FactorsMedical OncologyGastroenterologyInternal medicineBiomarkers TumorHumansMedicineTopic HighlightNeoplasm Stagingbusiness.industryIncidence (epidemiology)Liver NeoplasmsGastroenterologyExternal validationReproducibility of ResultsGeneral MedicinePrognosismedicine.diseasedigestive system diseasesEuropeNatural historyHepatocellular carcinomabusinessAlgorithmsWorld Journal of Gastroenterology
researchProduct

Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study

2013

AIM: To investigate clinical and biochemical features of hepatorenal syndrome (HRS), to assess short and long-term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients (53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and albumin, and three with albumin alone. No patients…

medicine.medical_specialtyCreatinineUnivariate analysisCirrhosisHepatologybusiness.industrymedicine.medical_treatmentLiver transplantationmedicine.diseaseGastroenterologySurgerychemistry.chemical_compoundLiver diseasechemistryHepatorenal syndromeInternal medicineAscitesmedicineOriginal Articlemedicine.symptomTerlipressinbusinesshepatorenal syndromemedicine.drug
researchProduct

Metabolic Factors and Chronic Hepatitis C: A Complex Interplay

2013

In the last years, several lines of evidence showed how metabolic factors may influence the natural history of patients with chronic hepatitis C. Chronic HCV infection is able to perturb the metabolic homeostasis of the host, in a context of complex interactions where pre-existent metabolic status and genetic background play an important role, allowing us to state that HCV infection is a systemic disease. In this review, we discuss the most recent lines of evidence on the main metabolic factors that are known to be associated with CHC, namely, insulin resistance/type 2 diabetes, steatosis, visceral obesity, atherosclerosis, vitamin D, menopause, fructose and coffee intake, lipoproteins, met…

Liver CirrhosisSystemic diseaselcsh:MedicineContext (language use)Review ArticleType 2 diabetesBiologyGeneral Biochemistry Genetics and Molecular BiologyInsulin resistanceRisk FactorsmedicineVitamin D and neurologyHumansHCV STEATOSIS METABOLIC SYNDROMEGeneral Immunology and Microbiologylcsh:RGeneral MedicineHepatitis C Chronicmedicine.diseaseMenopauseDiabetes Mellitus Type 2LiverMethylenetetrahydrofolate reductaseImmunologyDisease Progressionbiology.proteinInsulin ResistanceSteatosis
researchProduct

Causes of and prevention strategies for hepatocellular carcinoma.

2012

Hepatocellular carcinoma (HCC) is a challenging malignancy of global importance. It is associated with a high rate of mortality and its prevalence in the United States and in Western Europe is increasing. Cirrhosis is the strongest and the most common known risk factor for HCC, usually due to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. However, different lines of evidence identify in non-alcoholic fatty liver disease (NAFLD) a possible relevant risk factor for occurrence of HCC. Given the continuing increase in the prevalence of obesity and diabetes, the incidence of non-alcoholic steatohepatitis-related HCC may also be expected to increase, and a potential role of behav…

Counselingmedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeGastroenterologyChemopreventionInternal medicineMedicineHumansRisk factorHepatitis B virusbusiness.industryIncidence (epidemiology)Hepatocellular carcinoma primary prevention chemopreventionFatty liverLiver NeoplasmsVaccinationHematologymedicine.diseaseHepatitis BHepatitis Cdigestive system diseasesOncologyHepatocellular carcinomaControlled Clinical Trials as TopicInterferonsbusinessSeminars in oncology
researchProduct

Progressive multi-organ expression of immunoglobulin G4-related disease: A case report.

2012

A 63-year-old Caucasian man presented with a cholestatic syndrome, renal failure and arthralgias. A laboratory examination revealed high immunoglobulin G (IgG) and IgG4 levels (5.95 g/L; normal range: 0.08-1.4 g/L), pointing to a diagnosis of systemic IgG4-related disease, with definite radiological evidence of biliary and pancreatic expression, and plausible renal, articular, salivary and lacrimal glands involvement. Due to the rarity of the condition, there are currently no random control trials to point to the optimal therapeutic approach. The patient has been on steroid therapy with the subsequent introduction of azathioprine, with a complete resolution of all symptoms, a rapid reductio…

medicine.medical_specialtyPathologyHepatologybiologybusiness.industryAzathioprineCase ReportDiseaseMulti organmedicine.diseaseGastroenterologyImmunoglobulin GTherapeutic approachRadiological weaponImmunoglobulin g4Internal medicinemedicinebiology.proteinbusinessmedicine.drugAutoimmune pancreatitisWorld journal of hepatology
researchProduct

Young gastrointestinal angle: E-learning in gastroenterology: Future is now

2021

na

Medical educationOncologybusiness.industryE-learning (theory)MedicinegastroenterologygastrolearningNewsendoscopybusinessyoung GI angle.e-learning
researchProduct

Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 I…

2013

Background & Aims: Few studies have evaluated the accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C. We assessed its accuracy in detecting steatosis and factors that affect its diagnostic performance in consecutive patients with chronic hepatitis C virus genotype 1infection. Methods: We analyzed data from 515 patients with chronic hepatitis C, confirmed by liver biopsy, assessing anthropometric, biochemical, metabolic, virologic, and ultrasonography features. Transient elastography was performed to measure liver stiffness. Steatosis was identified with ultrasonography based on detection of a bright liver echo pattern. Results: Ultrasonography identified…

AdultMalemedicine.medical_specialtyCirrhosisGenotypeHepatitis C virusHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexPredictive Value of TestsInternal medicinemedicineHumansAgedSettore MED/12 - Gastroenterologiahcv fibrosis fibroscan steatosis histologyHepatologymedicine.diagnostic_testDiagnostic Tests Routinebusiness.industryGastroenterologyOdds ratioHepatitis C ChronicMiddle Agedmedicine.diseaseElasticityConfidence intervalFatty LiverLiverLiver biopsyElasticity Imaging TechniquesFemaleSteatosisbusinessTransient elastographyBody mass indexClinical Gastroenterology and Hepatology
researchProduct

Author Correction: Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study

2018

Binge drinking (BD) is a common pattern of alcohol consumption among adolescents. At present few data are available on the possible relationship between BD and alcohol use disorders (AUD) in adolescents. The aim of this study was to assess the prevalence of BD and relationship between BD behavior and AUD among adolescents. A total of 2704 students attending 10 purposively selected high schools from three Italian provinces were surveyed. Questionnaires regarding socio-demographic data, pattern and amount of alcohol intake, smoking habits, use of illicit drugs, and physical activity were administered. AUD and affective disorders were also evaluated. Alcohol intake was reported by 2126 partici…

MaleAdolescentAlcohol DrinkingCross-sectional studylcsh:MedicineBinge drinkingAlcoholBinge DrinkingYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSurveys and QuestionnairesEnvironmental healthPrevalenceHumanslcsh:ScienceAuthor CorrectionStudentsSchoolsMultidisciplinaryEthanollcsh:R030227 psychiatryAlcoholismCross-Sectional StudiesItalySocioeconomic FactorschemistryComputingMethodologies_DOCUMENTANDTEXTPROCESSINGlcsh:QFemalePsychology030217 neurology & neurosurgeryScientific Reports
researchProduct

Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies

2015

There have been many studies of the effects of hepatitis C virus (HCV) infection on cardiovascular risk, but these have produced ambiguous results. We performed a meta-analysis of these studies to systematically assess the risk of HCV infection on cardiovascular disease (CVD)-related morbidity and mortality.We searched PubMed Central, Medline, Embase, and Cochrane Library, as well as reference lists of articles, for studies published through July 2015 that compared the occurrence of CVD between HCV-infected and HCV-uninfected subjects, or assessed the prevalence of HCV infection among subjects with CVDs. In total, 22 studies were analyzed. Data on the patient populations and outcomes were e…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaBlood VesselComorbidityAntiviral AgentsSeverity of Illness IndexChronic Liver Disease03 medical and health sciences0302 clinical medicineCause of DeathInternal medicineSeverity of illnessmedicineHumans030212 general & internal medicineCause of deathSettore MED/12 - GastroenterologiaCirrhosiHepatologybusiness.industryIncidenceIncidence (epidemiology)GastroenterologyCase-control studyHepatitis COdds ratioHepatitis C ChronicPrognosismedicine.diseaseHepatitis CSurvival AnalysisComorbidityObservational Studies as TopicHeart DiseaseItalyCardiovascular DiseasesCase-Control StudiesMeta-analysisImmunologyFemale030211 gastroenterology & hepatologybusinessGastroenterology
researchProduct

Treatment of hepatocellular carcinoma: present and future

2013

Hepatocellular carcinoma is a major health problem. It is the sixth most common cancer worldwide and the third most common cause of cancer-related death. Despite the availability of several treatment opportunities, diagnosis is still made in an advanced phase, limiting application of most therapeutic choices that currently are based on the Barcelona Clinic Cancer Liver Classification and include surgical resection, orthotopic liver transplantation and ablative methods for very early and early disease, arterial chemoembolization for intermediate stages and systemic therapy with sorafenib for advanced hepatocellular carcinoma. Thanks to novel advancements in knowledge of molecular pathogenesi…

OncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularOrthotopic liver transplantationHepatocellular carcinomabusiness.industryLiver NeoplasmsCancermedicine.diseaseCombined Modality TherapySystemic therapyOncologyHepatocellular carcinomaInternal medicinemedicineCarcinomaAnimalsHumansCombined Modality TherapyPharmacology (medical)In patientbusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Hepatobiliary and Pancreatic: Portal hypertensive biliopathy presenting as acute cholangitis

2013

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMEDLINECholecystitisMedicineMagnetic resonance imagingRadiologybusinessmedicine.diseasePortographyJournal of Gastroenterology and Hepatology
researchProduct

P255 Efficacy and safety of a restrictive ferric carboxymaltose infusion strategy for iron deficiency anemia in inflammatory bowel disease patients

2021

Abstract Background Iron deficiency anemia (IDA) is a common condition in patients with inflammatory bowel disease (IBD) and ferric carboxymaltose (FCM) has shown fast correction of hemoglobin (Hb) levels and good tolerability. We evaluated the response to FCM in IBD patients with IDA. The primary outcome was the assessment of the rate of response to single or multiple FCM infusions after 12 months from the first infusion. Secondary outcomes were the response to a single FCM infusion after 3 months and the assessment of FCM safety. Methods We retrospectively included 185 consecutive patients from IBD Unit of “Villa Sofia-V. Cervello” Hospital who received at least a dose of 500 mg FCM infus…

medicine.medical_specialtyUnivariate analysisbusiness.industryAnemiaGastroenterologyGeneral Medicinemedicine.diseaseInflammatory bowel diseaseGastroenterologyFERRIC CARBOXYMALTOSEIron-deficiency anemiaInternal medicineInfusion ProceduremedicineHemoglobinbusinessAdverse effectJournal of Crohn's and Colitis
researchProduct

The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease

2015

In nonalcoholic fatty liver disease, the influence of severity of steatosis on liver stiffness measurement (LSM) is poorly studied and still debated. We assessed the impact of steatosis severity and its ultrasonographic (US) sign, severe bright liver echo pattern, on LSM values and on transient elastography accuracy for the diagnosis of liver fibrosis in a cohort of consecutive patients with nonalcoholic fatty liver disease. Patients (n = 253) were assessed by clinical, US, and histological (Kleiner score) features. Transient elastography was performed using the M probe. Among patients with low amounts of fibrosis (F0-F1 and F0-F2), median LSM values, expressed in kilopascals, were signific…

Settore MED/12 - Gastroenterologiamedicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industrySettore MED/08 - Anatomia PatologicaHepatologymedicine.diseaseGastroenterologyFibrosisInternal medicineLiver biopsySeverity of illnessCohortNonalcoholic fatty liver diseasemedicineLSM FIBROSIS NAFLDSteatosisbusinessTransient elastographyHepatology
researchProduct

Microbiota Gut–Brain Axis in Ischemic Stroke: A Narrative Review with a Focus about the Relationship with Inflammatory Bowel Disease

2021

The gut microbiota is emerging as an important player in neurodevelopment and aging as well as in brain diseases including stroke, Alzheimer’s disease, and Parkinson’s disease. The complex interplay between gut microbiota and the brain, and vice versa, has recently become not only the focus of neuroscience, but also the starting point for research regarding many diseases such as inflammatory bowel diseases (IBD). The bi-directional interaction between gut microbiota and the brain is not completely understood. The aim of this review is to sum up the evidencesconcerningthe role of the gut–brain microbiota axis in ischemic stroke and to highlight the more recent evidences about the potential r…

0301 basic medicinebrainScienceGut–brain axisReviewDiseaseGut floraBioinformaticsInflammatory bowel diseasedigestive systemGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineinflammatory bowel diseasemicrobiotaMedicineStrokeEcology Evolution Behavior and Systematicsbiologybusiness.industrystroke.digestive oral and skin physiologyQPaleontologyInflammatory Bowel Diseasesbiology.organism_classificationmedicine.diseasestrokestomatognathic diseases030104 developmental biologySpace and Planetary ScienceIschemic strokegutNarrative reviewbusiness030217 neurology & neurosurgeryLife
researchProduct

P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease

2021

Abstract Background The role of Vedolizumab (VDZ) as therapeutic option for the postoperative recurrence of Crohn’s disease (CD) following ileocolonic resection is currently unknown. We aimed to assess the effectiveness of VDZ in this setting. Methods All consecutive CD patients with an available baseline colonoscopy at 6-12 months from the ileocolonic resection and treated with VDZ for the postoperative recurrence after the baseline colonoscopy were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was endoscopic success, assessed at the first colonoscopy following initiation of VDZ. In patients with Rutgeerts score i0 or i1 at …

medicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyGeneral Medicinemedicine.diseaseGastroenterologyInflammatory bowel diseaseEndoscopyVedolizumabInternal medicinemedicinebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

Imaging appearance of treated hepatocellular carcinoma

2013

Surgical resection and imaging guided treatments play a crucial role in the management of hepatocellular carcinoma (HCC). Although the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and has a key role in HCC decision-making process. However, radiological assessment of HCC treatment efficacy is often controversial. There are few doubts on the evaluation of surgical resection; in fact, all known tumor sites should be removed. However, an unenhancing partial linear peripheral halo, in most cases, surrounding a fluid collection reducing in size during follow-up is demonstrated in successfully resected tumor with bipolar radio…

medicine.medical_specialtyPercutaneousHepatologySurrogate endpointbusiness.industryRadiofrequency ablationmedicine.medical_treatmentHepatocellular carcinoma Imaging TreatmentMinireviewsmedicine.diseaseAblationSurgerylaw.inventionTumor progressionlawHepatocellular carcinomamedicineClinical endpointPercutaneous ethanol injectionbusiness
researchProduct

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

2018

Background &amp; Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurren…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaSustained Virologic ResponseHepacivirusGastroenterology0302 clinical medicineRESIST-HCVRisk FactorsHepatocellular Carcinoma (HCC)MedicineLiver Cancer RiskProspective StudiesProspective cohort studySettore MED/12 - GastroenterologiaIncidence (epidemiology)IncidenceLiver NeoplasmsGastroenterologyHepatitis CMiddle AgedCirrhosis; Direct Antiviral Agents (DAAs); Hepatocellular Carcinoma (HCC); RESIST-HCV; Sustained Virological Response (SVR); hepatitis C Virus (HCV); liver cancer risk; reduction; sofosbuvirCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomahepatitis C Virus (HCV)030211 gastroenterology & hepatologyFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularDirect Antiviral Agents (DAAs)Liver CirrhosiRESIST-HCV Liver Cancer Risk Reduction SofosbuvirAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicineHumansIn patientSustained Virological Response (SVR)AgedReductionAntiviral AgentHepaciviruHepatologybusiness.industryProportional hazards modelRisk FactorHepatitis C Chronicmedicine.diseasedigestive system diseasesProspective StudieChild-Pugh Class BSofosbuvirbusinessFollow-Up Studies
researchProduct

Personalized sorafenib therapy for hepatocellular carcinoma

2013

OncologySorafenibmedicine.medical_specialtyHepatologybusiness.industryHepatocellular carcinomaInternal medicineGastroenterologymedicinemedicine.diseasebusinessmedicine.drugDigestive and Liver Disease
researchProduct

Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological …

2013

Background: Radio-frequency ablation (RFA) has been employed in the treatment of Barcelona Clinic Liver Cancer (BCLC) early stage hepatocellular carcinoma (HCC) as curative treatments. Aim: To assess the effectiveness and the safety of RFA in patients with early HCC and compensated cirrhosis. Methods: A cohort of 151 consecutive patients with early stage HCC (122 Child-Pugh class A and 29 class B patients) treated with RFA were enrolled. Clinical, laboratory and radiological follow-up data were collected from the time of first RFA. A single lesion was observed in 113/151 (74.8%), two lesions in 32/151 (21.2%), and three lesions in 6/151 (4%) of patients. Results: The overall survival rates …

Malemedicine.medical_specialtyCirrhosisPercutaneousCarcinoma HepatocellularClinical Research Designmedicine.medical_treatmentCancer Treatmentlcsh:MedicineCatheter ablationGastroenterology and HepatologyGastroenterologyCohort StudiesInternal medicineGastrointestinal CancersGastrointestinal TumorsmedicineHumansStage (cooking)lcsh:ScienceAgedMultidisciplinaryRadiotherapybusiness.industryLiver Diseaseslcsh:RLiver NeoplasmsCancers and NeoplasmsHepatocellular CarcinomaMiddle Agedmedicine.diseaseAblationFibrosisdigestive system diseasessurgical procedures operativeTreatment OutcomeCirrhosisOncologyRadiological weaponHepatocellular carcinomaCatheter AblationMedicineHepatocellular carcinoma survival RFAlcsh:QFemalebusinessLiver cancerResearch ArticlePloS one
researchProduct

Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort

2016

Background: Natural history of primary biliary cirrhosis (PBC) is partially characterized in patients from the Mediterranean area whose genetic background differs from that of Northern Europeans. Objectives: We aimed to describe genetic susceptibility and clinical course of PBC in patients from Southern Italy. Methods: Socio-demographic, clinical, biochemical and histological data at diagnosis as well as disease progression of 81 PBC consecutive patients were collected. All subjects were treated with Ursodeoxycholic acid at a dose of 15 mg/kg. HLA class II DRB1 alleles were compared with those of 237 healthy control subjects. IL28B genotyping for IL28B rs12979860 C/T and rs80899917 G/T was …

0301 basic medicinemedicine.medical_specialtyPrimary biliary cirrhosimedicine.medical_treatmentLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicinePrimary biliary cirrhosisGeneticInternal medicineGenotypemedicineGenetic predispositionProspective cohort studySettore MED/04 - Patologia GeneraleAutoimmune diseaseSettore MED/12 - GastroenterologiaPrimary Biliary CirrhosisHepatologybusiness.industrymedicine.diseaseKowsarTransplantation030104 developmental biologyInfectious DiseasesGenetic; Natural history; Primary biliary cirrhosis; Hepatology; Infectious Diseases030211 gastroenterology & hepatologybusinessResearch ArticleNatural HistoryHepatitis Monthly
researchProduct

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study

2012

Abstract AIM: To investigate the clinical course of untreatable hepatocellular carcinoma (HCC) identified at any stage and to identify factors associated with mortality. METHODS: From January 1999 to December 2010, 320 out of 825 consecutive patients with a diagnosis of HCC and not appropriate for curative or palliative treatments were followed and managed with supportive therapy. Cirrhosis was diagnosed by histological or clinical features and liver function was evaluated according to Child-Pugh score. The diagnosis of HCC was performed by Ultra-Sound guided biopsy or by multiphasic contrast-enhanced computed tomography or gadolinium-enhanced magnetic resonance imaging. Data were collected…

Oncologymedicine.medical_specialtyBrief ArticleHepatologybusiness.industryClinical courseCancerRetrospective cohort studymedicine.diseasedigestive system diseasesSurgeryNatural historyInternal medicineHepatocellular carcinomamedicinehepatocellular carcinoma survival natural historyStage (cooking)businessWorld Journal of Hepatology
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study.

2014

Abstract Background Drugs and herbal products can induce autoimmune hepatitis. We assessed frequency and clinical outcomes of patients suffering from drug-induced autoimmune hepatitis. Methods All patients with drug-induced liver injury admitted between 2000 and 2011 were retrospectively studied. Diagnoses of drug-induced autoimmune hepatitis and idiopathic autoimmune hepatitis were made according to simplified criteria. After discharge, all patients had regular follow-up and were contacted to update outcomes. Results Among 10,270 in-hospital patients, 136 (1.3%) were diagnosed with drug-induced liver injury. Among them, 12 (8.8%) were diagnosed as drug-induced autoimmune hepatitis (41.7% m…

AdultMalemedicine.medical_specialtyDrug-induced liver injuryAdolescentAutoimmunityAutoimmune hepatitisSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyAutoimmunityYoung AdultInternal medicinemedicineHumansAutoimmunity; Drug-induced liver injury; Human leucocyte antigens; Liver biopsy --------------------------------------------------------------------------------Liver biopsy --------------------------------------------------------------------------------AgedRetrospective StudiesSettore MED/04 - Patologia GeneraleLiver injurySettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyGamma globulinRetrospective cohort studyHuman leucocyte antigenJaundiceMiddle Agedmedicine.diseaseHepatitis AutoimmuneTreatment OutcomeLiver biopsyCohortImmunologyFemalemedicine.symptomChemical and Drug Induced Liver InjurybusinessImmunosuppressive AgentsFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or …

2018

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansPharmacology (medical)business.industryIncidenceIncidence (epidemiology)Liver Neoplasmsmedicine.diseaseHepatitis CTreatment Outcome030104 developmental biologyOncologyHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessExpert Review of Anticancer Therapy
researchProduct

Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes

2021

There is a growing need for biomarkers to predict therapeutic outcome in Crohn's disease (CD).The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics.Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn's disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calcul…

0301 basic medicineOncologymedicine.medical_specialtyNeutrophilsClinical BiochemistryDisease03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicineDrug DiscoverymedicineHumansLymphocytesRetrospective StudiesPharmacologyBiological ProductsCrohn's diseasebusiness.industryfungiOutcome measuresPrognosismedicine.diseaseInflammatory biomarkers030104 developmental biology030220 oncology & carcinogenesisMucosal healingbusinessBiomarkersExpert Opinion on Biological Therapy
researchProduct

TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C

2016

Background & Aims We tested the putative association of the rs58542926 variant of TM6SF2, a recently described genetic determinant of nonalcoholic fatty liver disease, with steatosis and fibrosis in genotype 1(G1) chronic hepatitis C(CHC) patients. Methods A total of 694 consecutively biopsied Caucasian G1 CHC patients were genotyped for TM6SF2 rs58542926, IL28B rs12979860 and PNPLA3 rs738409. Steatosis was classified as absent (<5%), mild-moderate(5–29%) and severe(≥30%), Fibrosis was considered severe if=F3-F4. Results Carriers of TM6SF2 rs58542926 (6.3% of patients) exhibited lower serum levels of cholesterol (P = 0.04) and triglycerides (P = 0.01), but a similar distribution of steatosi…

0301 basic medicineLiver CirrhosisMalesteatosiIL28BStatistics as TopicGastroenterologySeverity of Illness IndexCohort Studies0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseMembrane ProteinFatty liverHepatitis CMiddle AgedItalyLiver030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLiver Cirrhosisteatosis; CHC; IL28B; PNPLA3; TM6SF2; Adult; Cohort Studies; Female; Hepatitis C Chronic; Humans; Interleukins; Italy; Lipase; Liver; Male; Membrane Proteins; Middle Aged; Severity of Illness Index; Statistics as Topic; Fatty Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; HepatologyTM6SF203 medical and health sciencesInternal medicineSeverity of illnessmedicineHumansPNPLA3Hepatologybusiness.industryInterleukinsMembrane ProteinsOdds ratioLipaseHepatologyHepatitis C ChronicInterleukinmedicine.diseaseFatty LiverCHC030104 developmental biologyEndocrinologyInterferonsSteatosisCohort Studiebusiness
researchProduct

Management of antiplatelet or anticoagulant therapy in endoscopy: A review of literature

2020

Endoscopic procedures hold a basal risk of bleeding that depends on the type of procedure and patients' comorbidities. Moreover, they are often performed in patients taking antiplatelet and anticoagulants agents, increasing the potential risk of intraprocedural and delayed bleeding. Even if the interruption of antithrombotic therapies is undoubtful effective in reducing the risk of bleeding, the thromboembolic risk that follows their suspension should not be underestimated. Therefore, it is fundamental for each endoscopist to be aware of the bleeding risk for every procedure, in order to measure the risk-benefit ratio for each patient. Moreover, knowledge of the proper management of antithr…

Riskmedicine.medical_specialtymedicine.drug_classReview03 medical and health sciencesDigestive endoscopy0302 clinical medicineAntithromboticmedicineAntiplateletIn patientIntensive care medicineGastrointestinal endoscopymedicine.diagnostic_testPotential riskbusiness.industryBleedingAnticoagulantAnticoagulantEndoscopyManagementEndoscopyAnticoagulant therapy030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessWorld Journal of Gastrointestinal Endoscopy
researchProduct

Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.

2016

NAFLD (Non-Alcoholic Fatty Liver Disease) is an increasingly significant public health issue, regarded as the most relevant liver disease of the twenty-first century. Approximately 20%-30% of NAFLD subjects develop a NASH (Non-Alcoholic Steato-Hepatitis), a condition which can potentially evolve to liver cirrhosis and hepatocellular carcinoma. For these reasons a proper evaluation of liver damage is a key point for diagnosis and prognosis and liver biopsy still remains the "gold standard" procedure both for discrimination between steatosis and steatohepatitis and assessment of the degree of liver fibrosis. Nonetheless, given it is an invasive, painful and costly procedure, a great research …

medicine.medical_specialtyCirrhosisFibrosiBiopsyClinical Decision-MakingApoptosis030204 cardiovascular system & hematologyBiochemistryGastroenterologyMultimodal Imaging03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineAnimalsHumansMortalityMolecular BiologyLiver injurymedicine.diagnostic_testAnimalbusiness.industryFatty liverApoptosiBiomarkerGeneral Medicinemedicine.diseasePrognosisFibrosisdigestive system diseasesAlgorithmLiverLiver biopsyHepatocellular carcinomaMolecular Medicine030211 gastroenterology & hepatologySteatosisSteatohepatitisMorbiditybusinessAlgorithmsBiomarkersHumanCurrent molecular medicine
researchProduct

Screening and surveillance for hepatocellular carcinoma: perspective of a new era?

2016

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death with an increasing prevalence worldwide. Early diagnosis of HCC is important since observational studies have reported that, in patients undergoing surveillance, cancer is diagnosed at an earlier stage with increased chances of curative therapies. Anyway, despite the extensive use of screening for HCC, its effectiveness is still a controversial topic since supporting evidence is not unequivocal and some issues need to be explored. Areas covered: The aim of this paper is to review main literature data supporting performance and effectiveness of screening for early detection …

medicine.medical_specialtyCarcinoma HepatocellularEarly detectionGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansMass ScreeningPharmacology (medical)In patientStage (cooking)Intensive care medicineCancer specific mortalityEarly Detection of CancerNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industryLiver NeoplasmsCancermedicine.diseasedigestive system diseasesOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation Surveillance030211 gastroenterology & hepatologyObservational studybusinessExpert review of anticancer therapy
researchProduct

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection

2011

Background and aims: Steatosis and insulin resistance (IR) are the major disease modifying in patients with chronic hepatitis C (CHC). Only few studies evaluated these features in patients with chronic hepatitis B (CHB). We aimed to assess the prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, and to evaluate the potential association between these features and fibrosis severity. Material and methods: One hundred and seventy consecutive patients with CHB (28 HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and metabolic measurements and matched for sex, age and body mass index with 170 genotype 1 CHC patients. IR was def…

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industryDiseasemedicine.diseaseGastroenterologyInsulin resistanceHBeAgFibrosisLiver biopsyInternal medicineBiopsyImmunologymedicineSteatosisbusinessBody mass indexLiver International
researchProduct

Could Chronic Idiopatic Intestinal Pseudo-Obstruction Be Related to Viral Infections?

2021

Chronic idiopathic intestinal pseudo-obstruction (CIIPO) is a disease characterized by symptoms and signs of small bowel obstruction in the absence of displayable mechanical obstruction. Due to the known neuropathic capacity of several viruses, and their localization in the intestine, it has been hypothesized that such viruses could be involved in the pathogenesis of CIIPO. The most frequently involved viruses are John Cunningham virus, Herpesviridae, Flaviviruses, Epstein–Barr virus and Citomegalovirus. Therefore, the present narrative review aims to sum up some new perspectives in the etiology and pathophysiology of CIIPO.

Intestinal pseudo-obstructionmedicine.medical_specialtyviruseslcsh:MedicineReviewvirusDiseasemedicine.disease_causeGastroenterologyHerpesviridaeVirusPathogenesis03 medical and health sciences0302 clinical medicineInternal medicinemedicinebusiness.industrylcsh:Rgastrointestinal motility disordersGeneral Medicinemedicine.diseasePathophysiologyBowel obstructionchronic idiopathic intestinal pseudo-obstruction030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologybusinessJournal of Clinical Medicine
researchProduct

Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience

2017

The occurrence of thiopurine-related adverse events (AEs) may complicate the management of patients with inflammatory bowel disease (IBD). We aimed to evaluate the tolerability of thiopurines in a current IBD setting.All consecutive patients who started a treatment with azathioprine (AZA) from January 2010 to March 2016 were entered in a prospectively maintained database, and the AEs which led to the permanent discontinuation of the drug were reported.Two hundred and fifty three patients were included. Median total follow-up was 32 months (range: 0.2-75 months). At the end of the study, AZA was discontinued in 160 patients (63.2%). The main reason leading to drug withdrawal was the occurren…

AdultMalemedicine.medical_specialtyNauseaAzathioprineKaplan-Meier EstimateInflammatory bowel disease03 medical and health sciencesDrug withdrawal0302 clinical medicineInternal medicineAzathioprinemedicineHumansCumulative incidenceProspective StudiesAdverse effectMercaptopurinebusiness.industryGastroenterologyNauseaMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurgeryDiscontinuationItalyTolerability030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologymedicine.symptombusinessImmunosuppressive Agentsmedicine.drugScandinavian Journal of Gastroenterology
researchProduct

Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment

2014

SorafenibOncologymedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseTumor progressionInternal medicineHepatocellular carcinomamedicineIn patientbusinessmedicine.drugDigestive and Liver Disease
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

2018

Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinoma (HCC) was recently proposed to optimize treatment allocation. The aim of this study was to assess the prognostic ability of that substaging proposal. Patients and methods This is a retrospective multicenter cohort study including patients with intermediate HCC treated with transarterial chemoembolization (TACE). Predictors of survival were identified using the Cox proportional regression model. Results 289 Barcelona Clinic Liver Cancer (BCLC) B patients were included. Medi…

MaleTime FactorsSpecialties of internal medicineKaplan-Meier EstimateGastroenterologyChemoembolization; Liver cancer; Radioembolization; Sorafenib; Staging system; Hepatology0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsGeneral MedicineMiddle AgedSorafenibTreatment OutcomeRC581-951Italy030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleChemoembolizationLiver cancerLiver cancerCohort studymedicine.drugSorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIARisk AssessmentDecision Support Techniques03 medical and health sciencesPredictive Value of TestsInternal medicineHumansChemoembolization TherapeuticRadioembolizationAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryProportional hazards modelRetrospective cohort studymedicine.diseaseStaging systemLog-rank testMultivariate Analysisbusiness
researchProduct

Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes

2021

There is a growing need for biomarkers to predict therapeutic outcome in Crohn’s disease (CD). The aim was to evaluate whether NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio), ELR (eosinophil-to-lymphocyte ratio), and ENLR (eosinophil*neutrophil-to-lymphocyte ratio), could be prognostic biomarkers of endoscopic response (ER) when starting biologics. Patients with CD who started biologics were enrolled. Multivariate analysis was used to evaluate whether NLR, PLR, ELR and ENLR at baseline and at w12 could predict ER (Simple Endoscopic Score for Crohn’s disease [SES-CD] ≤2 or SES-CD≤2 and Rutgeerts i0-i1) after 52 weeks of treatment. Area under the curve (AUC) was calc…

researchProduct